Christopher Daniels, MD
Interventional Cardiology · Thomasville, GANPI 1952519670
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,332 of the $120,484 with a category attached, or 65.8%. Johnson & Johnson accounts for 70.3% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $66,446 and has fallen 92.2% since, to $5,212 in 2025. Among interventional cardiology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 707 payments — averaging $170.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$85K
- Angiodynamics, Inc.$13K
- Abbott$5K
- Bard Peripheral Vascular, Inc.$3K
- Cardiovascular Systems Inc.$3K
- Medtronic$3K
- plus $8K from 32 others
Across 42 payments — averaging $7000.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$171K
- Boehringer Ingelheim Pharma GmbH & Co.kg$50K
- Merck$32K
- Boehringer Ingelheim International GmbH$32K
- Alnylam Pharmaceuticals Inc.$10K
What the payments were for
- Speaking & faculty fees$79,33266%
- Travel & lodging$11,2309%
- Food & beverage$17,55915%
- Education$2130%
- Other$12,15010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 148 | $84,714 |
| Angiodynamics, Inc. | 9 | $12,560 |
| Abbott | 52 | $5,086 |
| Bard Peripheral Vascular, Inc. | 49 | $3,448 |
| Cardiovascular Systems Inc. | 30 | $3,199 |
| Medtronic(2 entities) | 51 | $3,124 |
| Abiomed | 15 | $1,270 |
| Novartis | 67 | $1,129 |
| AstraZeneca | 44 | $1,040 |
| Shockwave Medical, Inc | 35 | $897 |
| Boston Scientific | 13 | $544 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $472 |
| Amgen | 25 | $427 |
| E.r. Squibb & Sons, L.L.C. | 30 | $417 |
| Pfizer | 28 | $408 |
| Penumbra, Inc. | 12 | $322 |
| Merck | 17 | $291 |
| Boehringer Ingelheim | 13 | $270 |
| Stryker | 1 | $140 |
| Sanofi-aventis U.S. LLC | 6 | $128 |
| Novo Nordisk | 4 | $82 |
| Alnylam Pharmaceuticals Inc. | 4 | $76 |
| Arbor Pharmaceuticals, Inc. | 4 | $60 |
| Itamar Medical Inc | 1 | $52 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Cvrx, Inc. | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Acist Medical Systems, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Roche Diagnostics Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Inari Medical, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$82,306
- Auryon Laser System 100-120 Vac$12,399
- AVEIR$3,197
- Peripheral Orbital Atherectomy System$2,112
- Impella$857
- Micra$524
- Coronary Orbital Atherectomy System$482
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$327
- Omnilink Elite vascular stent system$298
- AVVIGO Guidance System$225
- CoreValve Evolut$188
- CARDIOMEMS$148
- AZURE XT DR MRI SURESCAN$148
- LIMFLOW SYSTEM$140
- Indigo System$127
- MyCareLink$127
- Diamondback Peripheral$122
- Diamondback Coronary$122
- RotarexS 6 F x 135 cm$121
- ATTAIN PERFORMA MRI SURESCAN$112
How this compares
$120,484 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 72 | $1,584,144 |
| EliquisApixaban | 605 | $470,442 |
| EntrestoSacubitril/Valsartan | 297 | $220,787 |
| FarxigaDapagliflozin Propanediol | 280 | $196,404 |
| XareltoRivaroxaban | 246 | $177,483 |
| Repatha SureclickEvolocumab | 159 | $112,409 |
| BrilintaTicagrelor | 155 | $97,638 |
| JardianceEmpagliflozin | 108 | $89,186 |
| Ranolazine ErRanolazine | 468 | $31,139 |
| MultaqDronedarone Hcl | 18 | $21,431 |
| Metoprolol Succinate | 1,156 | $12,734 |
| VascepaIcosapent Ethyl | 31 | $11,372 |
| CorlanorIvabradine Hcl | 13 | $10,321 |
| EdarbiAzilsartan Medoxomil | 20 | $8,567 |
| Atorvastatin Calcium | 910 | $7,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $408 | $2,054,586677 claims |
| AstraZenecaFarxiga, Brilinta | $1,040 | $294,042435 claims |
| NovartisEntresto | $1,129 | $220,787297 claims |
| Johnson & JohnsonXarelto | $84,714 | $177,483246 claims |
| Boehringer IngelheimJardiance | $270 | $89,186108 claims |
| Sanofi-aventis U.S. LLCMultaq | $128 | $21,43118 claims |
| AmgenCorlanor | $427 | $10,32113 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $60 | $8,56720 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $43 | $5,53512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Thomasville
- Byron SizemoreThomasville$148K
- Kelechukwu OkoroThomasville$30K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.